FDAnews
www.fdanews.com/articles/73053-biovex-announces-relocation-of-headquarters-to-the-u-s

BioVex Announces Relocation of Headquarters to the U.S.

June 6, 2005

BioVex, a developer of new generation vaccines for the treatment and prevention of cancer and chronic infectious disease, announced the relocation of its headquarters from the UK to Cambridge, Mass. BioVex will base its clinical, finance and business development operations in Massachusetts. The company will retain its research function in the UK. Philip Astley-Sparke, president and CFO of BioVex, will serve as operational head in the U.S.

Canada NewsWire (http://www.newswire.ca/en/releases/archive/June2005/06/c7988.html)